Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Chemotherapy in Second-line Advanced Gastric Cancer
NCT05669807Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2022
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05669807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669807.